Kandrozid (Candesartan Cilexetil)

After oral absorption, candesartan cilexetil is converted to candesartan, which selectively blocks AT1 receptors. This prevents angiotensin II‑mediated vasoconstriction and aldosterone release, leading to vessel relaxation, reduced sodium and water retention, and ultimately lower blood pressure.

The exact dose is set by the prescribing clinician based on the patient’s blood‑pressure target, presence of heart failure or kidney disease, renal function, and any concomitant medications. Dosage adjustments may be required for elderly patients or those with impaired renal function.

Candesartan cilexetil is classified as Pregnancy Category D, indicating evidence of fetal risk. It should not be used during pregnancy. Limited data are available for breastfeeding; therefore, use is generally discouraged unless the benefit outweighs the potential risk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kandrozid belongs to the ARB class, offering similar blood‑pressure control to other ARBs but with a lower incidence of cough compared with ACE inhibitors. Its long half‑life allows once‑daily dosing, and it provides proven benefits in heart‑failure patients, making it a convenient alternative for many clinicians.

Kandrozid tablets should be stored at temperatures below 25 °C, in the original container, protected from moisture and direct sunlight. Do not store in a bathroom or near a heat source, and keep out of reach of children.

Kandrozid is taken orally, usually once daily, with or without food. Swallow the tablet whole with a full glass of water. Patients should follow the prescribing physician’s instructions regarding timing and any dose adjustments.

The most serious adverse events include angioedema, severe hypotension, acute renal failure, and hyperkalaemia. Patients should be instructed to seek immediate medical attention if they experience swelling of the face or throat, sudden dizziness, marked weakness, or unexplained changes in kidney function.

Kandrozid is contraindicated in patients who are pregnant, have severe hepatic impairment, have a known hypersensitivity to candesartan or any component of the formulation, or have experienced angioedema with previous ARB or ACE‑inhibitor therapy.